Conversion Surgery Reduces Mortality in Metastatic Colorectal Cancer

Conversion surgery significantly reduced mortality risk by 42% in patients with unresectable metastatic colorectal cancer treated with anti-EGFR agents and bevacizumab. Subgroup analyses showed reduced risks of mortality in patients with specific characteristics. While targeted therapy reduced mortality risk, the difference was not statistically significant between the two treatment groups. Conversion surgery may explain the disparity in survival outcomes between anti-EGFR agents and bevacizumab in colorectal cancer patients.